Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,422 | 0,552 | 07:50 | |
0,630 | 0,680 | 04.07. |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
Do | CARMAT Announces the Initiation of a Call for Public Tenders (Buyers or Investors) as Part of the Receivership Procedure | 295 | Business Wire | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
Mi | XFRA CXT: WIEDERAUFNAHME/RESUMPTION | 116 | Xetra Newsboard | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
01.07. | Carmat files for insolvency | 7 | MassDevice | ||
01.07. | CARMAT Announces Its Placement in Receivership Procedure | 212 | Business Wire | Resumption of CARMAT shares trading starting July 2, 2025, at stock market opening
Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial... ► Artikel lesen | |
30.06. | XFRA CXT: AUSSETZUNG/SUSPENSION | 146 | Xetra Newsboard | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILCARMAT EO -,04 CXT... ► Artikel lesen | |
30.06. | CARMAT Announces Filing Today for Insolvency and Requesting Being Placed in Receivership | 330 | Business Wire | Suspension of CARMAT shares trading starting June 30, 2025, before stock market opening
Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total... ► Artikel lesen | |
24.06. | Carmat is running out of cash | 5 | MassDevice | ||
CARMAT Aktie jetzt für 0€ handeln | |||||
20.06. | In a Context of Critical Financial Situation, CARMAT Launches a Donation Campaign Open to All to Contribute to Its Funding and Continuation of Its Activities | 327 | Business Wire | Risk of insolvency as early as end of June 2025
Launch of a donation campaign open to all via the onparticipe.fr online platform
To listen to CARMAT CEO's message,
click here
Regulatory... ► Artikel lesen | |
20.06. | CARMAT Announces Being in a Critical Financial Situation and at Risk of Insolvency as of End-June 2025 | 381 | Business Wire | Immediate need to secure approximately €3.5 million to avoid insolvency at the end of June 2025
Total funding needs of around €35 million over the next 12 months
Ongoing active exploration... ► Artikel lesen | |
02.06. | CARMAT Announces the First Commercial Implants of Its Aeson Artificial Heart Outside the European Union | 327 | Business Wire | Two implants have recently been performed in Israel
Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide... ► Artikel lesen | |
12.05. | CARMAT Completes Enrolment in the EFICAS Clinical Study and Receives Approval From French Authorities for 21 Additional Aeson Implants, While Awaiting Potential Reimbursement of the Device in France | 270 | Business Wire | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
30.04. | CARMAT: Availability of the 2024 Universal Registration Document | 360 | Business Wire | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
29.04. | CARMAT Announces Its 2024 Annual Results | 440 | Business Wire | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
14.04. | CARMAT Receives FDA Conditional Approval to Initiate the Second Cohort of the EFS Study in the United States | 284 | Business Wire | Recruitment of the second cohort expected to begin in H2 2025
Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming... ► Artikel lesen | |
09.04. | CARMAT Delivers Q1 2025 Results in Line With Its Objectives | 280 | Business Wire | Quarterly sales of €2.4m multiplied by 2.4 vs Q1 2024
EFICAS clinical trial recruitment 94% complete
2 scientific publications a strong driver of Aeson® adoption
Final stage... ► Artikel lesen | |
03.04. | CARMAT - Publication in the JACC(1): Heart Failure of the Initial Clinical Experience with Aeson Total Artificial Heart in Cardiogenic Shock Patients Initially Placed on Extracorporeal Life Support | 321 | Business Wire | The retrospective analysis on 10 patients shows a 90% survival rate at 6 months, suggesting Aeson® as a therapeutic solution for these patients at risk of death in the short term.
Regulatory News:
CARMAT... ► Artikel lesen | |
31.03. | CARMAT to Provide a Business Update and Host a Videoconference on April 9, 2025 | 306 | Business Wire | Please register to the videoconference by clicking on one of the following links: Videoconference in French at 6:00 pm CEST -
Videoconference in English at 8:00 pm CEST
Regulatory News:
CARMAT... ► Artikel lesen | |
27.03. | CARMAT announces the implementation of a flexible equity financing line with IRIS Capital Investment | 412 | Business Wire | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen | |
17.02. | CARMAT: Aeson total artificial heart highlighted as a very promising solution for heart failure patients with pulmonary hypertension in The Journal of Heart and Lung Transplantation | 542 | Business Wire | Up to 25% of advanced heart failure patients suffer from pulmonary hypertension
Aeson® could potentially become a standard treatment for these thousands of patients, both as a bridge-to-transplant... ► Artikel lesen | |
10.02. | CARMAT Achieves the Milestone of 100 Implants of Its Aeson Total Artificial Heart | 379 | Business Wire | Regulatory News:
CARMAT (FR0010907956, ALCAR), designer and developer of the world's most advanced total artificial heart, aiming to provide a therapeutic alternative for people suffering from... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
FRESENIUS | 42,430 | -0,12 % | Aktie von Fresenius SE & Co. KGaA: Kurs heute nahezu konstant (42,73 €) | Die Wertschätzung für den Anteilsschein von Fresenius SE & Co. KGaA hat sich am Aktienmarkt heute kaum geändert. Das Wertpapier notiert zur Stunde bei 42,73 Euro. Kaum auffällig ist derzeit an der Börse... ► Artikel lesen | |
FRESENIUS MEDICAL CARE | 47,940 | +0,36 % | EQS-PVR: Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution | EQS Voting Rights Announcement: Fresenius Medical Care AG
Fresenius Medical Care AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act]... ► Artikel lesen | |
SIEMENS HEALTHINEERS | 46,600 | -0,28 % | DEUTSCHE BANK RESEARCH stuft Siemens Healthineers auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Siemens Healthineers vor Zahlen von 67 auf 62 Euro gesenkt, aber die Einstufung auf "Buy" belassen. Falko Friedrichs rechnet... ► Artikel lesen | |
CARL ZEISS MEDITEC | 52,40 | -2,24 % | GOLDMAN SACHS stuft CARL ZEISS MEDITEC AG auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat das Kursziel für Carl Zeiss Meditec von 77 auf 74 Euro gesenkt, aber die Einstufung auf "Buy" belassen. Das dritte Geschäftsquartal... ► Artikel lesen | |
ECKERT & ZIEGLER | 66,50 | +0,15 % | UNGLAUBLICHE Sondermeldung bei Eckert & Ziegler Aktie: DAS erwischt Anleger heute eiskalt. Dringend lesen und reagieren! | ||
DRAEGERWERK | 65,90 | +0,76 % | Draegerwerk AG & Co. KGaA: Konstruktive Präsentation auf der mwb research-Konferenz; mwb research empfiehlt HALTEN | Auf der gestrigen mwb research Health Care Conference bestätigte Drägers Head of Investor Relations, Thomas Fischler, den Ausblick für das Geschäftsjahr 2025 (Umsatzwachstum 1-5%, EBIT-Marge 3,5-6,5%)... ► Artikel lesen | |
MEDTRONIC | 74,78 | -0,05 % | Medtronic reports first patient treated in study of multi-organ denervation for hypertension | ||
INTUITIVE SURGICAL | 457,00 | +0,13 % | ISRG da Vinci 5 Gets European Nod: Will it Boost the Stock's Prospect? | ||
UNITEDHEALTH | 259,30 | +0,06 % | Kurs der UnitedHealth Group steigt etwas (273,4951 €) | Das Wertpapier der UnitedHealth Group notiert heute ein wenig fester. Die Aktie kostete zuletzt 322,18 US-Dollar. Am Aktienmarkt liegt die Aktie der UnitedHealth Group zur Stunde im Plus. Das Papier... ► Artikel lesen | |
GERRESHEIMER | 48,600 | -0,16 % | Gerresheimer-Aktie verliert 3,41 Prozent (46,48 €) | Der Anteilsschein von Gerresheimer notiert heute etwas leichter. Die Aktie kostete zuletzt 46,48 Euro. Ein Abschlag von 3,41 Prozent steht gegenwärtig für der Anteilsschein von Gerresheimer zu Buche.... ► Artikel lesen | |
TELADOC HEALTH | 6,833 | -0,83 % | Aktien-Trading 4 Dummies - 3 Aktien. 2 Experten. 0 Langeweile (Hims & Hers, Teladoc & XTI Aerospace) | ||
THERMO FISHER | 357,00 | -0,11 % | Thermo Fisher Scientific: Günstige Einstiegschance | Thermo Fisher Scientific zeigt derzeit vielversprechende Anzeichen für eine nachhaltige Wachstumsphase. Die Kernbereiche Bioproduktion und Pharma-Dienstleistungen beginnen sich zu erholen, während innovative... ► Artikel lesen | |
STRATEC | 26,500 | -1,30 % | Video: STRATEC-CEO Wolfinger auf der Health Care Conference von mwb research | Video von STRATEC-CEO Marcus Wolfinger auf der Health Care Conference von mwb research: Der Manager hat eine aktuelle Präsentation zu den Zahlen, dem Ausblick und der Strategie des SDAX-notierten Unternehmen... ► Artikel lesen | |
RHOEN-KLINIKUM | 12,000 | -1,64 % | RHÖN-KLINIKUM Campus Bad Neustadt erhält Bayerischen Organspendepreis für herausragendes Engagement | Bad Neustadt a.d. Saale (ots) - Bayerns Gesundheits- und Pflegeministerin Judith Gerlach hat am Donnerstag (26.06.) in München gemeinsam mit der Deutschen Stiftung Organtransplantation (DSO) im Rahmen... ► Artikel lesen | |
ADAPTHEALTH | 9,250 | -0,75 % | AdaptHealth stock maintains Buy rating at Truist after infusion asset sale |